Asai Tomohiro, Miyazawa Souichiro, Maeda Noriyuki, Hatanaka Kentaro, Katanasaka Yasufumi, Shimizu Kosuke, Shuto Satoshi, Oku Naoto
Department of Medical Biochemistry and Global COE, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Cancer Sci. 2008 May;99(5):1029-33. doi: 10.1111/j.1349-7006.2008.00758.x. Epub 2008 Feb 24.
Causing damage to angiogenic vessels is a promising approach for cancer chemotherapy. The present study is a codification of a designed liposomal drug delivery system (DDS) for antineovascular therapy (ANET) with 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). The authors have previously reported that liposomalized 5'-O-dipalmitoylphosphatidyl CNDAC (DPP-CNDAC), a phospholipid derivative of the novel antitumor nucleoside CNDAC, is quite useful for ANET. DPP-CNDAC liposomes modified with APRPG, a peptide having affinity toward angiogenic vessels, efficiently suppressed tumor growth by damaging angiogenic endothelial cells. In the present study, the authors masked the hydrophilic moiety of DPP-CNDAC, namely, CNDAC, on the liposomal surface with APRPG-polyethyleneglycol (PEG) conjugate to improve the availability of DPP-CNDAC liposomes. The use of the APRPG-PEG conjugate attenuated the negative zeta-potential of the DPP-CNDAC liposomes and reduced the agglutinability of them in the presence of serum. These effects improved the blood level of DPP-CNDAC liposomes in colon 26 NL-17 tumor-bearing BALB/c male mice, resulting in enhanced accumulation of them in the tumor. Laser scanning microscopic observations indicated that APRPG-PEG-modified DPP-CNDAC liposomes (LipCNDAC/APRPG-PEG) colocalized with angiogenic vessels and strongly induced apoptosis of tumor cells, whereas PEG-modified DPP-CNDAC liposomes (LipCNDAC/PEG) did not. In fact, LipCNDAC/APRPG-PEG suppressed the tumor growth more strongly compared to LipCNDAC/PEG and increased significantly the life span of the mice. The present study is a good example of an effective liposomal DDS for ANET that is characterized by: (i) phospholipid derivatization of a certain anticancer drug to suit the liposomal formulation; (ii) PEG-shielding for masking undesirable properties of the drug on the liposomal surface; and (iii) active targeting to angiogenic endothelial cells using a specific probe.
破坏血管生成血管是癌症化疗的一种有前景的方法。本研究是一种设计用于抗血管生成治疗(ANET)的脂质体药物递送系统(DDS)的编纂,该系统使用2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶(CNDAC)。作者此前曾报道,新型抗肿瘤核苷CNDAC的磷脂衍生物脂质体化的5'-O-二棕榈酰磷脂酰CNDAC(DPP-CNDAC)对ANET非常有用。用对血管生成血管具有亲和力的肽APRPG修饰的DPP-CNDAC脂质体通过破坏血管生成内皮细胞有效地抑制了肿瘤生长。在本研究中,作者用APRPG-聚乙二醇(PEG)共轭物掩盖脂质体表面DPP-CNDAC的亲水部分,即CNDAC,以提高DPP-CNDAC脂质体的可用性。APRPG-PEG共轭物的使用减弱了DPP-CNDAC脂质体的负ζ电位,并降低了它们在血清存在下的凝集性。这些作用提高了DPP-CNDAC脂质体在荷结肠26 NL-17肿瘤的BALB/c雄性小鼠中的血药浓度,导致它们在肿瘤中的蓄积增加。激光扫描显微镜观察表明,APRPG-PEG修饰的DPP-CNDAC脂质体(LipCNDAC/APRPG-PEG)与血管生成血管共定位,并强烈诱导肿瘤细胞凋亡,而PEG修饰的DPP-CNDAC脂质体(LipCNDAC/PEG)则没有。事实上,与LipCNDAC/PEG相比,LipCNDAC/APRPG-PEG更强烈地抑制肿瘤生长,并显著延长小鼠的寿命。本研究是一种有效的用于ANET的脂质体DDS的良好范例,其特点是:(i)对某种抗癌药物进行磷脂衍生化以适合脂质体制剂;(ii)用PEG屏蔽以掩盖药物在脂质体表面的不良性质;(iii)使用特异性探针主动靶向血管生成内皮细胞。